Related Experiment Video
Updated: May 31, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
Severe thrombocytopenia related to trastuzumab infusion
Marina Mantzourani1, Helen Gogas, Aikaterini Katsandris
11st Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens, Greece.
Background:
Trastuzumab is a humanized, monoclonal antibody that interferes with the HER2/neu receptor and binds selectively to the HERB2 protein which causes uncontrolled proliferation of malignant breast cells.
Case Report:
We report a case of severe thrombocytopenia related to trastuzumab administration. Three days after the first dose of single-agent trastuzumab, the patient was admitted to the hospital with nose bleeding, petechiae and platelet counts of 5 × 10⁹/L.
Conclusions:
The patient showed a self-limiting trastuzumab-related thrombocytopenia. Among the reported cases of trastuzumab-induced severe thrombocytopenia, this patient is the only one who did not interrupt trastuzumab treatment. It is possible that our patient showed progressive reduction of immune-mediated thrombocytopenia caused by trastuzumab administration.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Venous Thrombosis III: Interprofessional Care
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
